4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no…